For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.
Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.
Commented by Fabian Lorenz
Commented by Fabian Lorenz on June 12th, 2025 | 07:10 CEST
Short squeeze, hedge funds, and summer rally: Plug Power, Novo Nordisk, Power Metallic Mines
Is Power Metallic Mines poised for a summer rally? There are certainly good reasons to believe so: Following the discovery of its world-class multi-metal project, the stock has consolidated healthily. At the same time, further positive drilling results were reported, followed by a massive expansion of the area this week. Now, an extensive new drilling program is getting underway. Plug Power has shown in recent days how quickly a stock can rise by 50%. The insolvency candidate has delivered several pieces of positive news, and a short squeeze could drive the stock further. At Novo Nordisk, investors are realizing that the sell-off in recent months may have been too severe. The stock is working on a new upward trend. A hedge fund and a partnership in the AI sector are providing tailwinds.
Read
Commented by Fabian Lorenz on June 11th, 2025 | 07:00 CEST
Revolution in a billion-dollar market! Argo Living Soils shares surge! Soon to be a takeover target?
Argo Living Soils is focusing on its business model this year and has a clear goal: to revolutionize the construction industry. Nanotechnology is set to make concrete and asphalt more durable and environmentally friendly. Buildings and bridges, for example, will be better protected against earthquakes thanks to this "miracle material." At the same time, emissions will be reduced, as the cement industry is one of the world's biggest polluters. The potential is in the billions. Argo Living is still valued at less than CAD 10 million. If progress is made on the road to market launch, a takeover attempt is likely. CAD 100 million should not be a problem for interested parties. There are several reasons to add this stock to your portfolio.
Read
Commented by Fabian Lorenz on June 10th, 2025 | 07:00 CEST
Up more than 1,000%! Siemens Energy and D-Wave! Insider tip First Hydrogen shares jump after announcement!
Siemens Energy stock is a tenbagger! Anyone brave enough in fall 2023 to buy the shares despite speculation about insolvency can now look forward to a price gain of over 1,000%. The reason is the growing appetite for energy demand from artificial intelligence and quantum computing. The latest news from the Company shows where the journey is headed. In the US, in particular, tech companies are focusing on small modular reactors (SMRs). First Hydrogen is another insider tip in this area. The partnership announced yesterday sounds promising and sent the stock soaring. Its valuation still appears attractive. Anything but favorable is D-Wave Quantum after its 2,000% rally - yet this does not appear to be deterring investors. The latest news is driving the stock further.
Read
Commented by Fabian Lorenz on June 9th, 2025 | 07:15 CEST
BioNTech billion-dollar deal a template for BioNxt Solutions? Bayer shares recommended as a buy!
The billion-dollar deal between BioNTech and Bristol-Myers Squibb was a real bombshell and has revitalized the biotech industry. While analysts are raising their price targets for the German biotech high-flyer, there are also critical voices. Investors are also wondering where Big Pharma will strike next. One potential candidate for a partnership is BioNxt Solutions. The Company aims to simplify drug administration using oral dissolvable films, skin patches, and tablets. Clinical trials are about to begin on the development of its lead product for the easier treatment of multiple sclerosis, and a key patent has just been granted in Europe. Due to its low valuation and universal application possibilities, a complete takeover is also conceivable. And what is Bayer doing? Despite numerous legal proceedings, the stock is performing well in 2025. Analysts see further upside potential and have upgraded the stock.
Read
Commented by Fabian Lorenz on June 5th, 2025 | 07:10 CEST
Almonty shares are unstoppable! Tungsten price hits 12-year high! Are analysts too conservative?
The commodity stock of the year is poised for its next leap: Almonty Industries. Yesterday, the tungsten gem surged above EUR 2, reaching a new all-time high. However, this is likely a stopover on the road to revaluation. Analysts continue to see 80% upside potential. There are both short- and long-term price drivers: Tungsten appears to be overtaking rare earths in terms of desirability and scarcity. China is limiting exports and driving the price to a 12-year high. The US is alarmed and buying tungsten on a large scale. Almonty is the direct beneficiary. Experts are calling the latest deal with a US defense contractor "unprecedented." Almonty is about to bring the largest tungsten mine outside of China into operation, plans a NASDAQ listing, and aims to add molybdenum to its portfolio. Are the analysts' estimates too conservative? Will a complete takeover follow?
Read
Commented by Fabian Lorenz on June 3rd, 2025 | 07:20 CEST
A bombshell and a buying opportunity! BioNTech, Bayer, and AI stock NetraMark
Bombshell news from BioNTech. The Company has announced a collaboration for its cancer pipeline - billions in revenue are on the horizon. The stock has surged significantly. Are there other exciting buying opportunities in the biotech and pharma sectors right now? US politics have recently dampened industry sentiment. The Trump administration wants to lower drug prices. One potential beneficiary is NetraMark, as this AI gem helps industry cut development costs and timelines. In addition, takeover speculation could drive the stock in the second half of the year. And what is Bayer doing? The stock has outperformed the DAX in 2025. Are there reasons to consider buying?
Read
Commented by Fabian Lorenz on June 3rd, 2025 | 07:10 CEST
SHOCK for RENK, "BUY" rating for Novo Nordisk, and PanGenomic Health follows in the footsteps of Hims & Hers
Shock for RENK & Co.! Yesterday afternoon, news broke that the EU plans to tap into the billions in profits made by defense companies. After all, these companies are facing a golden age. The shares ended their record run yesterday. The alternative medicine and dietary supplements sector is currently experiencing a boom in the US. PanGenomic Health wants a piece of that multi-billion-dollar market. The newcomer is launching an AI-based app offering recommendations, a marketplace, and diagnostics. The rollout will begin this summer. Anyone who missed out on the 800% gains at Hims & Hers should take a look at this newcomer. Novo Nordisk is a core investment in the pharmaceutical sector. However, expectations for the blockbuster drug Ozempic were likely set too high. After the stock's crash, things are now looking better again.
Read
Commented by Fabian Lorenz on June 2nd, 2025 | 07:15 CEST
Alarm bells ringing for rare earths and record highs for hydrogen! Hensoldt, Plug Power, Mercedes, and BMW partner European Lithium
Rare earths are increasingly being used as a weapon in geopolitics. "The last remaining stocks will likely be used up within four to six weeks. Then parts of production will have to be shut down," warns Christian Grimmelt of the consulting firm Berylls by AlixPartners in Wirtschaftswoche. This could benefit European Lithium's stock. The Company not only aims to supply lithium to BMW but is also developing a rare earths project in Greenland. Is the defense industry also affected by the shortage of raw materials? Perhaps. For now, the FOMO rally is driving defense stocks to new all-time highs. But caution is advised: according to analysts, Hensoldt shares, for example, have a 30% downside risk. Plug Power, on the other hand, has had to cope with many setbacks in recent months. Its shares are at rock bottom. Could a milestone in its home market bring about a turnaround?
Read
Commented by Fabian Lorenz on May 30th, 2025 | 07:00 CEST
D-Wave shares with insider alert! Nel and Samsung step on the gas! Walmart partner MiMedia makes a big splash!
Insider alert at D-Wave Quantum. Numerous executives have sold shares in recent weeks, taking advantage of the quantum highflyer's record levels to take profits. Should investors do the same? There was positive news at MiMedia. On Wednesday, the cloud hidden gem announced a new partnership with a smartphone manufacturer. Is the stock now heading for a new all-time high? In any case, the valuation appears attractive. At Nel, new major shareholder Samsung is increasingly taking the reins. In addition to the change in the board of directors, a joint product was presented. Will the struggling hydrogen play manage a turnaround?
Read
Commented by Fabian Lorenz on May 29th, 2025 | 07:10 CEST
Rheinmetall unstoppable! Evotec shorted! Sensational news at Vidac Pharma! And what is BioNTech doing?
Sensational news at Vidac Pharma. Last year's biotech highflyer has published strong results for its cancer drug. The share price rose by 5% yesterday. Does this mean the consolidation is over? Analysts certainly see potential for a multiplication in value. Rheinmetall shares have gained over 200% this year alone. Analysts are raising their price targets and continue to recommend buying. Operationally, a lot is happening at the defense company. Meanwhile, Evotec has run out of steam operationally. The stock has become a plaything for takeover speculators and short sellers — who will win? BioNTech also wants to win the fight against cancer. Will the stock gain new momentum in the coming days?
Read